| Literature DB >> 34021152 |
Stéphane Le Vu1, Gabrielle Jones2, François Anna3, Thierry Rose4, Jean-Baptiste Richard5, Sibylle Bernard-Stoecklin2, Sophie Goyard4, Caroline Demeret6, Olivier Helynck7, Nicolas Escriou8, Marion Gransagne8, Stéphane Petres9, Corinne Robin10, Virgile Monnet11, Louise Perrin de Facci12, Marie-Noelle Ungeheuer12, Lucie Léon13, Yvonnick Guillois14, Laurent Filleul15, Pierre Charneau3, Daniel Lévy-Bruhl2, Sylvie van der Werf6,16, Harold Noel2.
Abstract
Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05-0.88) mid-March, 4.14% (95% CI: 3.31-4.99) mid-April and 4.93% (95% CI: 4.02-5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70-1.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34021152 DOI： 10.1038/s41467-021-23233-6
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919